Znaczenie farmakoterapii w leczeniu uzależnienia od alkoholu

Andrzej Jakubczyk

1.  Mann K, Hermann D, Individualised treatment in alcohol-dependent patients. Eur Arch Psychiatry Clin Neurosci. 2010; 260 Suppl 2:S116-20.
2.  Barth KS, Malcolm RJ, Disulfiram: an old therapeutic with new applications. CNS Neurol Disord Drug Targets. 9(1):5-12.
3. Johnson BA, Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008; 75(1):34-56.
4. Diehl A, Ulmer L, Mutschler J, Herre H, Krumm B, Croissant B, Mann KKiefer F, Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. Alcohol Alcohol. 45(3):271-7.
5.  de Sousa A, An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2005; 40(6):545-8.
6.  de Wit H, Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol. 2009; 14(1):22-31.
7.  Garbutt JC, The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat. 2009; 36(1):S15-23; quiz S24-5.
8.  Swift R, Emerging approaches to managing alcohol dependence. Am J Health Syst Pharm. 2007; 64(5 Suppl 3):S12-22.
9.  Hall RC, Platt DE, Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts. Evaluation of suicide risk in a time of managed care. Psychosomatics. 1999; 40(1):18-27.
10. Ager CR, Ferrer HP, Fillmore KM, Golding JM, Leino EV, Motoyoshi M, Aggregate-level predictors of the prevalence of selected drinking patterns in multiple studies: a research synthesis from the Collaborative Alcohol-Related Longitudinal Project. Subst Use Misuse. 1996; 31(11-12):1503-23.
11.  Roberts AJ, McDonald JS, Heyser CJ, Kieffer BL, Matthes HW, Koob GF, Gold LH, mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther. 2000; 293(3):1002-8.
12.  Garbutt JC, Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des. 16(19):2091-7.
13.  Herz LR, Volicer L, D'Angelo N, Gadish D, Additional psychiatric illness by Diagnostic Interview Schedule in male alcoholics. Compr Psychiatry. 1990; 31(1):72-9.
14. Stack K, Cortina J, Samples C, Zapata M, Arcand LF, Race, age, and back pain as factors in completion of residential substance abuse treatment by veterans. Psychiatr Serv. 2000; 51(9):1157-61.
15. Rosner S, Leucht S, Lehert P, Soyka M, Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008; 22(1):11-23.
16. Srisurapanont M, Jarusuraisin N, Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005; (1):CD001867.
17. Litman GK, Alcoholism survival: the prevention of relapse, in Treating Addictive Behaviors, W.R. Miller and N. Heather, Editors. 1986, Plenum: New York. p. 391-405.
18.  Bouza C, Angeles M, Munoz A, Amate JM, Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004; 99(7):811-28.
19. Soyka M, Rosner S, Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review. Curr Drug Abuse Rev. 2008; 1(3):280-91.
20. Gastfriend DR, Garbutt JC, Pettinati HM, Forman RF, Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat. 2007; 33(1):71-80.
21. Mann JJ, Psychobiologic predictors of suicide. J Clin Psychiatry. 1987; 48 Suppl:39-43.
22. Mann K, Kiefer F, Smolka M, Gann H, Wellek S, Heinz A, Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Alcohol Clin Exp Res. 2009; 33(4):674-83.
23. Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T, Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol. 2001; 36(5):419-25.
24. Kiehl KA, Smith AM, Hare RD, Liddle PF, An event-related potential investigation of response inhibition in schizophrenia and psychopathy. Biol Psychiatry. 2000; 48(3):210-21.
25. Feeney GF, Connor JP, Young RM, Tucker J, McPherson A, Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006; 41(3):321-7.
26. Anton RE, Randall CL, Measurement and choice of drinking outcome variables in the COMBINE Study. J Stud Alcohol Suppl. 2005; (15):104-9; discussion 92-3.
27. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006; 295(17):2003-17.
28. Arbaizar B, Diersen-Sotos T, Gomez-Acebo I, Llorca J, Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr. 38(1):8-12.
29. Ray LA, Heydari A, Zorick T, Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug Alcohol Rev. 29(5):568-75.
30. Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I, Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol. 2004; 24(5):532-5.
31. Martin LE, Potts GF, Reward sensitivity in impulsivity. Neuroreport. 2004; 15(9):1519-22.
32. Kostowski W, Neurofizjologiczne mechanizmy uzależnień: znaczenie zachowań impulsywnych. Farmakoterapia w psychiatrii i neurologii. 2005; 2(93-102).
33. Kovacs M, Beck AT, Weissman A, Hopelessness: an indicator of suicidal risk. Suicide. 1975; 5(2):98-103.
34. Krampe H, Stawicki S, Wagner T, Bartels C, Aust C, Ruther E, Poser W, Ehrenreich H, Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res. 2006; 30(1):86-95.
35. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J, Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000; 284(8):963-71.
36. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B, Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry. 1992; 49(8):599-608.
37. Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C, Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res. 2003; 27(7):1150-5.
38. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A, Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000; 24(7):1041-9.
39. Kranzler HR, Burleson JA, Brown J, Babor TF, Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996; 20(9):1534-41.
40. Biblarz A, Brown RM, Biblarz DN, Pilgrim M, Baldree BF, Media influence on attitudes toward suicide. Suicide Life Threat Behav. 1991; 21(4):374-84.
41. Bisaga A, Evans SM, Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl). 2004; 172(1):16-24.
42. Evenden J, Impulsivity: a discussion of clinical and experimental findings. J Psychopharmacol. 1999; 13(2):180-92.
43. Adinoff B, Junghanns K, Kiefer F, Krishnan-Sarin S, Suppression of the HPA axis stress-response: implications for relapse. Alcohol Clin Exp Res. 2005; 29(7):1351-5.
44. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G, Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002; 37(5):504-8.
45. Nunes EV, Levin FR, Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. Jama. 2004; 291(15):1887-96.
46. Torrens M, Fonseca F, Mateu G, Farre M, Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 2005; 78(1):1-22.
47. Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP, Depression, sleep physiology, and antidepressant drugs. Depress Anxiety. 2001; 14(1):19-28.
48. Malec E, Malec T, Gagne MA, Dongier M, Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res. 1996; 20(2):307-12.
49. Brower KJ, Insomnia, alcoholism and relapse. Sleep Med Rev. 2003; 7(6):523-39.
50. Brower KJ, Alcohol's effects on sleep in alcoholics. Alcohol Res Health. 2001; 25(2):110-25.
51. Le Bon O, Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M, Dupont P, Lion K, Pelc I, Verbanck P, Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol. 2003; 23(4):377-83.
52. Karam-Hage M, Brower KJ, Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003; 57(5):542-4.
53. Croissant B, Klein O, Gehrlein L, Kniest A, Hermann D, Diehl A, Mann K, Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry. 2006; 21(8):570-3.
54. Hornyak M, Haas P, Veit J, Gann H, Riemann D, Magnesium treatment of primary alcohol-dependent patients during subacute withdrawal: an open pilot study with polysomnography. Alcohol Clin Exp Res. 2004; 28(11):1702-9.
55. Saitou K, Kaneko Y, Sugimoto Y, Chen Z, Kamei C, Slow wave sleep-inducing effects of first generation H1-antagonists. Biol Pharm Bull. 1999; 22(10):1079-82.